Teacher Retirement System of Texas Acquires 6,614 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Teacher Retirement System of Texas boosted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 127.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 11,815 shares of the company’s stock after buying an additional 6,614 shares during the quarter. Teacher Retirement System of Texas’ holdings in Janux Therapeutics were worth $633,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. FMR LLC boosted its stake in Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after acquiring an additional 47,075 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after acquiring an additional 721,563 shares during the period. Geode Capital Management LLC increased its position in Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after purchasing an additional 259,445 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Janux Therapeutics by 16.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 273,135 shares of the company’s stock valued at $14,624,000 after buying an additional 38,944 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Stifel Nicolaus increased their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Finally, Leerink Partners upped their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and an average price target of $92.44.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $29.10 on Monday. Janux Therapeutics, Inc. has a fifty-two week low of $28.91 and a fifty-two week high of $71.71. The firm has a market cap of $1.72 billion, a P/E ratio of -24.87 and a beta of 3.23. The firm has a 50-day simple moving average of $35.60 and a two-hundred day simple moving average of $46.01.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 293,054 shares in the company, valued at approximately $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 25,002 shares of company stock valued at $1,279,953. 29.40% of the stock is owned by company insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.